SG Americas Securities LLC Has $859,000 Holdings in Apogee Therapeutics Inc. $APGE

SG Americas Securities LLC lessened its holdings in shares of Apogee Therapeutics Inc. (NASDAQ:APGE) by 86.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,207 shares of the company’s stock after selling 63,055 shares during the quarter. SG Americas Securities LLC’s holdings in Apogee Therapeutics were worth $859,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Rockefeller Capital Management L.P. acquired a new stake in shares of Apogee Therapeutics during the fourth quarter worth approximately $25,000. Los Angeles Capital Management LLC purchased a new stake in Apogee Therapeutics in the 4th quarter worth approximately $37,000. Seven Fleet Capital Management LP acquired a new stake in shares of Apogee Therapeutics during the 4th quarter valued at $136,000. Ensign Peak Advisors Inc purchased a new position in shares of Apogee Therapeutics during the 4th quarter valued at $170,000. Finally, Quantbot Technologies LP purchased a new position in shares of Apogee Therapeutics during the 3rd quarter valued at $96,000. Institutional investors and hedge funds own 79.04% of the company’s stock.

Insider Buying and Selling

In related news, insider Carl Dambkowski sold 26,400 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $132.60, for a total value of $3,500,640.00. Following the completion of the sale, the insider directly owned 179,248 shares in the company, valued at approximately $23,768,284.80. The trade was a 12.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael Thomas Henderson sold 80,000 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $132.54, for a total value of $10,603,200.00. Following the sale, the chief executive officer directly owned 1,015,987 shares of the company’s stock, valued at $134,658,916.98. The trade was a 7.30% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 182,900 shares of company stock worth $20,690,585 over the last three months. 24.30% of the stock is owned by company insiders.

Apogee Therapeutics Stock Performance

Shares of NASDAQ:APGE opened at $132.91 on Monday. The stock has a market capitalization of $8.23 billion, a PE ratio of -30.70 and a beta of 0.32. Apogee Therapeutics Inc. has a 1 year low of $34.34 and a 1 year high of $133.85. The firm has a fifty day moving average price of $93.59 and a 200 day moving average price of $82.06.

Apogee Therapeutics (NASDAQ:APGE) last posted its earnings results on Monday, May 11th. The company reported ($1.06) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.01. On average, sell-side analysts forecast that Apogee Therapeutics Inc. will post -4.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on APGE shares. Guggenheim lowered Apogee Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, June 23rd. Royal Bank Of Canada boosted their target price on Apogee Therapeutics from $82.00 to $97.00 and gave the company a “sector perform” rating in a research note on Monday, June 8th. TD Cowen lowered Apogee Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 23rd. Rothschild & Co Redburn started coverage on Apogee Therapeutics in a research note on Friday, May 1st. They set a “buy” rating and a $140.00 price target for the company. Finally, Citigroup lowered Apogee Therapeutics from a “buy” rating to a “neutral” rating and lifted their price target for the company from $125.00 to $135.00 in a report on Tuesday, June 23rd. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $121.25.

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.